Wu Zhuang

机构：Fujian Provincial Cancer Hospital · ORCID：0000-0001-7381-4732

发表论文 9 篇 · 总被引 108 次 · h-index 6

代表论文

• Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study (2024 · Journal of Clinical Oncology · 被引 37)
• Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 21)
• A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer. (2022 · Journal of Clinical Oncology · 被引 19)
• The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC). (2022 · Journal of Clinical Oncology · 被引 12)
• Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis (2023 · Journal of Neuro-Oncology · 被引 11)
• A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC). (2022 · Journal of Clinical Oncology · 被引 7)